ReviewFrontiers in immunology2025
Metabolism of tumor infiltrating T cells.
Review in Frontiers in immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Spatiotemporal CD8Cancer science · 2026Review
- From barrier to trigger: leveraging tumor hypoxia for precise control of CAR-T cell activity.Molecular biology reports · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The microenvironment of solid tumor is commonly low in key nutrients such as glucose providing metabolic challenges for tumor infiltrating T lymphocytes (TIL), which upon activation switch to glycolysis to meet their need for energy and effector molecule production. Consequently, TIL become functionally impaired and die unless they can switch their metabolism to alternative pathways such as oxidative phosphorylation catabolizing lipids that are in ample supply within solid tumors. Medicinal interventions that alter the nutrient supply within tumors or that facilitate the TIL's metabolic switch away from glycolysis have been tested in experimental animals and clinical trials. Some of them were shown to increase TIL functions, prolong their survival and enable them to slow tumor progression.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.